C3 Nephropathy with Classic Pathway Involvement Responding to Iptacopan (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0728; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Discussion The abnormal C4b2a generation assay suggests that classical pathway dysfunction, such as C4Nef, lies upstream of the complement dysregulation in this case. Nonetheless, the prompt response to iptacopan points to alternative pathway amplification as the principal driver of active disease, supporting factor B inhibition as a viable strategy in C3G."
Complement-mediated Rare Disorders • Glomerulonephritis • Immunology • Infectious Disease • Lupus Nephritis • Monoclonal Gammopathy • Nephrology • Renal Disease
|
|
Ryosuke Kunishi; Yoshihiro Kawata; Mitsuru Yanai; Yayoi Ogawa; Makoto Araki
|